Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
PEGS Boston SummitPEGS Boston Summit
Not Confirmed
Not Confirmed
11 May-15 November, 2026
Pharmex Middle EastPharmex Middle East
Not Confirmed
Not Confirmed
26-28 May, 2026
Not Confirmed
Not Confirmed
27-28 May, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS






Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
PEGS Boston SummitPEGS Boston Summit
Industry Trade Show
Not Confirmed
11 May-15 November, 2026
Pharmex Middle EastPharmex Middle East
Industry Trade Show
Not Confirmed
26-28 May, 2026
Industry Trade Show
Not Confirmed
27-28 May, 2026
Digital content

19 May 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/05/19/3297346/0/en/zenas-biopharma-announces-upcoming-presentation-of-results-from-phase-3-indigo-registrational-trial-of-obexelimab-in-immunoglobulin-g4-related-disease-igg4-rd-at-eular-2026-congres.html

18 May 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/05/18/3297026/0/en/zenas-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html

13 May 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/05/13/3293773/0/en/zenas-biopharma-reports-first-quarter-2026-financial-results-and-provides-corporate-update.html

13 May 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/05/13/3293817/0/en/zenas-biopharma-announces-first-subject-dosed-in-phase-1-clinical-trial-of-zb021-a-novel-potentially-best-in-class-oral-il-17aa-af-inhibitor.html

17 Apr 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/04/17/3276496/0/en/Zenas-BioPharma-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

27 Mar 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/03/27/3263539/0/en/Zenas-BioPharma-Announces-Pricing-of-Concurrent-Public-Offerings-of-2-50-Convertible-Senior-Notes-Due-2032-and-Common-Stock-with-Aggregate-Gross-Proceeds-of-300-0-Million.html
ABOUT THIS PAGE